Previous 10 |
- Conference Call and Webcast Today, February 26, 2019, at 8:00 a.m. ET - Ophthotech Corporation (Nasdaq: OPHT) today announced financial and operating results for the fourth quarter and full year ended December 31, 2018 and provided a business update. “2018 was a signifi...
Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its fourth quarter and full year 2018 financial and operating results on Tuesday, February 26, 2019. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:0...
NEW YORK, Feb. 08, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Amerco (NASDAQ:UHAL), McKesson Corporation (NYSE:MCK), Ophthotech Corp...
- Preclinical Proof-of-Concept Results in a Large Animal Model Published Online Ahead of Print in PNAS - Ophthotech Corporation (NASDAQ: OPHT) announced today that scientists at the University of Pennsylvania (Penn) and University of Florida published proof-of-concept study results on...
NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Energy Recovery, Inc. (NASDAQ:ERII), Lamb Weston Holdings Inc. (NYSE:LW),...
Ophthotech Corp (OPHT) Q2 2018 Earnings Conference Call August 01, 2018, 08:00 ET Executives Kathy Galante - VP, IR & Corporate Communications Glenn Sblendorio - CEO, President & Director Kourous Rezaei - SVP & Chief Medical Officer David Carroll - SVP, CFO & T...
News, Short Squeeze, Breakout and More Instantly...
Ophthotech Corporation Company Name:
OPHT Stock Symbol:
NASDAQ Market:
Ophthotech Corporation Website:
- Company’s Shares Will Trade Under New Ticker Symbol: ISEE – Ophthotech Corporation (Nasdaq:OPHT) today announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IR...
Ophthotech Corporation (NASDAQ: OPHT) announced today that the Company has converted its option and entered into an exclusive global license agreement with the University of Pennsylvania (Penn), including the Perelman School of Medicine at the University of Pennsylvania and the University ...
Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Alliance for Regenerative Medicine’s (ARM) 7 th Annual Cell and Gene Therapy Investor Day in New York, NY, on Thursday, March 21...